IsoPlexis Announces Pricing of Initial Public Offering

BRANFORD, Conn., Oct. 7, 2021 /PRNewswire/ — IsoPlexis Corporation (“IsoPlexis”), a leader in functional single-cell proteomics, today announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by IsoPlexis. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IsoPlexis, are expected to be $125.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. IsoPlexis’ common stock is expected to begin trading on The Nasdaq Global Select Market on October 8, 2021, under the ticker symbol “ISO.” The offering is expected to close on October 12, 2021, subject to the satisfaction of customary closing conditions. In addition, IsoPlexis has granted the underwriters a 30-day option to purchase up to an additional 1,249,950 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting as lead book-running managers for the offering.

A registration statement on Form S-1 relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on October 7, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at [email protected]; or SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]. Copies of the final prospectus, when available, related to the offering will be available at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IsoPlexis
IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new ‘omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies by revenue and by nearly half of comprehensive cancer centers in the U.S.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of IsoPlexis Corporation, including those set forth in the Risk Factors section of the registration statement, the preliminary prospectus included therein, and, when available, the final prospectus. Copies are available on the SEC’s website at IsoPlexis Corporation undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Investor Contact
[email protected]

Press Contact
[email protected]

SOURCE IsoPlexis

Related Links

Leave a comment